FDA OKs Novel Fixed-Duration Oral Combo for Untreated CLL

(MedPage Today) — The FDA approved acalabrutinib (Calquence) plus venetoclax (Venclexta) for previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma as the first all-oral, fixed-duration regimen in the frontline setting…